In a current Phase I clinical trial, the WEE1 kinase inhibitor adavosertib (AZD1775) has exhibited beneficials effects on TP53 mutants in the context of HNSCC [32]. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.